Valentín García‐Gutiérrez

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 493 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Andreas Hochhaus, Tamás Masszi, Francis J. Giles et al. · Leukemia · 2017 · 287 citations · Full text

Medicine, Hematology, Oncology +9

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 150 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

Alberto Álvarez‐Larrán, Arturo Pereira, Paola Guglielmelli et al. · Haematologica · 2016 · 147 citations · Full text

Medicine, Hematology, Pharmacology +17